We have previously reported in diabetic cardiomyopathy, a co-morbid inflammation driven condition, that CXCL10 is a pharmacologic target of sildenafil, a phosphodiesterase type 5 inhibitor (PDE5i), originally employed to treat erectile dysfunction and now more commonly used in SSc both for the management of Raynaud’s phenomenon (RP) and pulmonary artery hypertension (PAH), on the basis of its vascular effects [17,18,19,20,21]. Here, CXCL10 is linked to pulmonary arterial hypertension.